Ray Dalio's RMD Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 32.0K shares of ResMed Inc. (RMD) worth $8.75 M, representing 0.03% of the portfolio. First purchased in 2015-Q2, this long-term strategic position has been held for 42 quarters.
Based on 13F filings since 2013, Ray Dalio has maintained a long-term strategic position in RMD, representing a significant commitment to this investment thesis. Largest addition occurred in Q1 2022, adding 83.4K shares. Largest reduction occurred in Q2 2025, reducing 114.1K shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's ResMed (RMD) Holding Value Over Time
Track share changes against reported price movement
Quarterly ResMed (RMD) Trades by Ray Dalio
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2015 | +5,988 | New Buy | 5,988 | $56.45 |
| Q3 2015 | +7,800 | Add 130.26% | 13,788 | $50.99 |
| Q4 2015 | -13,788 | Sold Out | 13,788 | $0.00 |
| Q1 2016 | +49,576 | New Buy | 49,576 | $57.81 |
| Q2 2016 | -49,576 | Sold Out | 49,576 | $0.00 |
| Q1 2018 | +9,632 | New Buy | 9,632 | $98.42 |
| Q2 2018 | -4,067 | Reduce 42.22% | 5,565 | $103.50 |
| Q3 2018 | -5,565 | Sold Out | 5,565 | $0.00 |
| Q4 2018 | +8,119 | New Buy | 8,119 | $113.93 |
| Q1 2019 | -8,119 | Sold Out | 8,119 | $0.00 |
| Q1 2020 | +3,371 | New Buy | 3,371 | $147.43 |
| Q2 2020 | -3,371 | Sold Out | 3,371 | $0.00 |
| Q3 2020 | +36,425 | New Buy | 36,425 | $171.42 |
| Q4 2020 | +37,854 | Add 103.92% | 74,279 | $212.56 |
| Q1 2021 | +15,508 | Add 20.88% | 89,787 | $194.01 |
| Q2 2021 | +75,028 | Add 83.56% | 164,815 | $246.52 |
| Q3 2021 | -3,466 | Reduce 2.10% | 161,349 | $263.55 |
| Q4 2021 | +26,053 | Add 16.15% | 187,402 | $260.48 |
| Q1 2022 | +83,388 | Add 44.50% | 270,790 | $242.51 |
| Q2 2022 | -27,869 | Reduce 10.29% | 242,921 | $209.63 |
| Q3 2022 | +23,845 | Add 9.82% | 266,766 | $218.30 |
| Q4 2022 | -53,593 | Reduce 20.09% | 213,173 | $208.13 |
| Q1 2023 | -20,312 | Reduce 9.53% | 192,861 | $218.99 |
| Q2 2023 | -20,537 | Reduce 10.65% | 172,324 | $218.50 |
| Q3 2023 | +58,199 | Add 33.77% | 230,523 | $147.87 |
| Q4 2023 | -71,997 | Reduce 31.23% | 158,526 | $172.02 |
| Q1 2024 | -9,820 | Reduce 6.19% | 148,706 | $198.03 |
| Q2 2024 | +17,407 | Add 11.71% | 166,113 | $191.42 |
| Q3 2024 | -72,216 | Reduce 43.47% | 93,897 | $244.12 |
| Q4 2024 | -6,626 | Reduce 7.06% | 87,271 | $228.69 |
| Q1 2025 | +32,060 | Add 36.74% | 119,331 | $223.85 |
| Q2 2025 | -114,077 | Reduce 95.60% | 5,254 | $258.00 |
| Q3 2025 | +26,728 | Add 508.72% | 31,982 | $273.73 |
Ray Dalio's ResMed Investment FAQs
Ray Dalio first purchased ResMed Inc. (RMD) in Q2 2015, acquiring 5,988 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held ResMed Inc. (RMD) for 42 quarters since Q2 2015. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's largest addition to ResMed Inc. (RMD) was in Q1 2022, adding 270,790 shares worth $65.67 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 31,982 shares of ResMed Inc. (RMD), valued at approximately $8.75 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, ResMed Inc. (RMD) represents approximately 0.03% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio's peak holding in ResMed Inc. (RMD) was 270,790 shares, as reported at the end of Q1 2022. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.